Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Armstrong, April; Paul, Carle; Puig, Luis; Boehncke, Wolf-Henning; Freeman, Michael; Torii, Hideshi; Papp, Kim; Griffiths, Christopher E M; Blauvelt, Andrew; Reich, Kristian; Gooderham, Melinda; Terui, Tadashi; Renda, Lisa; Agada, Noah; Xu, Wen; Gallo, Gaia; Lebwohl, Mark G

doi:10.1007/s13555-019-00340-3

Scientific article

English

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

ContributorsArmstrong, April; Paul, Carle; Puig, Luis; Boehncke, Wolf-Henning; Freeman, Michael; Torii, Hideshi; Papp, Kim; Griffiths, Christopher E M; Blauvelt, Andrew; Reich, Kristian; Gooderham, Melinda; Terui, Tadashi; Renda, Lisa; Agada, Noah; Xu, Wen; Gallo, Gaia; Lebwohl, Mark G

Published inDermatology and Therapy, vol. 10, no. 1, p. 133-150

Publication date2020

Abstract

Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis.

Keywords

Adverse events
Etanercept
IL-17
Integrated analysis
Ixekizumab
Safety
Psoriasis

Affiliation entities

Research groups

Inflammation cutanée (919)

Citation (ISO format)

ARMSTRONG, April et al. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. In: Dermatology and Therapy, 2020, vol. 10, n° 1, p. 133–150. doi: 10.1007/s13555-019-00340-3